Ensifentrine is a novel PDE3 and 4 inhibitor

We are developing ensifentrine, the first inhaled treatment for respiratory diseases in a single molecule that inhibits both phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) resulting in bronchodilator and non-steroidal anti-inflammatory effects.